AccessibilityHelp
Jw (Cayman) Therapeutics logo

Jw (Cayman) Therapeutics(OTC) JWCTF

Market Cap$82.11MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2021)-93%
5 Year-92%
1 Year-62%
1 Month+0%
$0.20
-4.40%
-0.01Today
Jw (Cayman) Therapeutics last closing stock price
MetricPriceDate
Last closeUSD 0.202026-10-12
Jw (Cayman) Therapeutics stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+0%USD 0.202026-10-05
1 month+0%USD 0.202026-08-06
3 month+0%USD 0.202026-07-13
Year to date-43.83%USD 0.362025-12-22
1 year-61.6%USD 0.532025-09-30
3 year-19.21%USD 0.252023-10-10
5 year-91.91%USD 2.502021-10-12
Since inception-92.9%USD 2.852021-07-15

Jw (Cayman) Therapeutics Financials at a Glance

Market Cap

$82.11MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

CN¥463.46M

Net Income (TTM)

-CN¥951.29M

EPS (TTM)

-$0.12

P/E Ratio

-1.72

Dividend

$0.00

Beta (Volatility)

170.37 (High)

Price

$0.20

Volume

238,500

Open

$0.20

Previous Close

$0.20

Daily Range

$0.20 - $0.20

52-Week Range

$0.20 - $0.45

Estimated Earnings Date

Apr 1, 2027

JWCTF News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Jw (Cayman) Therapeutics

JW (Cayman) Therapeutics Co. Ltd is a biopharmaceutical company focused on developing advanced cell-based immunotherapeutic solutions for hematological cancers and solid tumors. The company specializes in innovative treatments, particularly Chimeric Antigen Receptor T-cell (CAR-T) therapies, leveraging patients' immune cells to combat cancer.

Products and Services
  • Carteyva (relmacabtagene autoleucel) for blood cancer treatment
  • JWCAR129, an autologous CAR-T therapy for multiple myeloma
  • JWATM204 and JWATM203, T-cell receptor therapies targeting hepatocellular carcinoma
Growth Outlook
  • Strong pipeline with multiple CAR-T therapies in clinical development
  • Increasing demand for innovative cancer treatments globally
  • Established in 2016, the company is positioned for future growth in the biotechnology sector
Financial Highlights
  • Recent quarterly revenue of 111.35 million CNY, showing growth potential
  • Cash and cash equivalents of 392.08 million CNY as of June 2026
  • Operating expenses reflect significant investment in research and development
JW (Cayman) Therapeutics is dedicated to addressing critical healthcare needs through its innovative therapies. The company's flagship product, Carteyva, is designed to treat various forms of blood cancer, while its expanding pipeline includes promising therapies for multiple myeloma and hepatocellular carcinoma. With a strong focus on research and development, JW (Cayman) Therapeutics aims to capitalize on the growing demand for advanced cancer treatments. The financial data indicates a commitment to innovation, with substantial investments in R&D, positioning the company for potential future success in the biotechnology industry.
AI Generated • Oct 7, 2026

Industry

Biotechnology

Sector

Health Care

Employees

314

CEO

Feng Tian

Website

www.jwtherapeutics.com

Headquarters

Shanghai, SH 200131, CN

JWCTF Financials

Key Financial Metrics (TTM)

Gross Margin

39.80%

Operating Margin

-95.03%

Net Income Margin

-116.75%

Return on Equity

-66.16%

Return on Capital

-29.51%

Return on Assets

-40.06%

Earnings Yield

-58.14%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$82.11MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

406.05M

Volume

238.50K

Avg. Volume

17.20K

Financials (TTM)

Gross Profit

CN¥212.40M

Operating Income

-CN¥141.62M

EBITDA

-CN¥456.79M

Operating Cash Flow

-CN¥269.02M

Capital Expenditure

-CN¥4.58M

Free Cash Flow

-CN¥273.60M

Cash & ST Invst.

CN¥392.08M

Total Debt

CN¥254.89M

Jw (Cayman) Therapeutics Performance Analysis

Jw (Cayman) Therapeutics annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31CNY 21,637,688353.1%
20232023-12-31CNY 24,538,50413.4%
20242024-12-31CNY 21,984,439-10.4%
20252025-12-31CNY 39,459,56079.5%
Jw (Cayman) Therapeutics sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-12-31-17.8%
Q22025-06-3048.9%
Q42025-12-3164.0%
Q22026-06-30-36.1%
Jw (Cayman) Therapeutics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31CNY -0.3112.5%
20232023-12-31CNY -0.26-14.0%
20242024-12-31CNY -0.20-24.7%
20252025-12-31CNY -0.19-6.4%
Jw (Cayman) Therapeutics sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-12-31-44.8%
Q22025-06-3023.8%
Q42025-12-31-6.3%
Q22026-06-3082.4%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

CN¥111.35M

+28.3%

Gross Profit

CN¥57.71M

+31.9%

Gross Margin

51.82%

N/A

Market Cap

$82.11MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$261.51K

N/A

Employees

314

N/A

Net Income

-CN¥50.43M

+79.0%

EBITDA

-CN¥61.84M

+68.2%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

CN¥392.08M

-54.9%

Total Debt

CN¥254.89M

-33.0%

Accounts Receivable

CN¥0.00

N/A

Inventory

CN¥50.94M

+0.7%

Long Term Debt

CN¥65.72M

-62.3%

Short Term Debt

CN¥189.17M

-8.2%

Return on Assets

-40.06%

N/A

Return on Invested Capital

-52.43%

N/A

Free Cash Flow

-CN¥88.55M

+53.7%

Operating Cash Flow

-CN¥87.48M

+53.5%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
^GSPCS&P 500
$7,623.68-0.01%
^DJIDJI
$52,215.16-0.01%
^IXICNASDAQ
$25,955.34-0.00%
BTCBitcoin
$80,332.00-0.01%

Trending Stocks

Symbol / CompanyPricePrice Chg
SPCXSpace Exploration Technologies
$147.49+1.89%
TAT&T
$20.93-7.96%
SOXLDirexion Shares ETF Trust - Direxion Daily Semiconductor Bull 3x ETF
$83.56+1.77%
NUNu Holdings
$15.16+2.92%

Questions About JWCTF

What is the current price of Jw (Cayman) Therapeutics?

Jw (Cayman) Therapeutics is trading at $0.20 per share.

What is the 52-week range for Jw (Cayman) Therapeutics?

Over the past 52 weeks, Jw (Cayman) Therapeutics has traded between $0.20 and $0.45.

How much debt does Jw (Cayman) Therapeutics have?

As of the most recent reporting period, Jw (Cayman) Therapeutics reported total debt of CN¥37.57M.

How much cash does Jw (Cayman) Therapeutics have on hand?

Jw (Cayman) Therapeutics reported CN¥71.99M in cash and cash equivalents in its most recent financial results.

What is Jw (Cayman) Therapeutics’s dividend yield?

Jw (Cayman) Therapeutics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services